Skip to main content
SpringerLink
Log in

American Thoracic Society

100 Years of Advances in the Treatment and Science of Respiratory Diseases; 20–25 May 2005; San Diego, California, USA

  • Meeting Report
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

  2. Tiotropium: Influence sur la Perception de l’amelioration des activites Habituelles Objectivee par une echelle Numerique.

References

  1. Humbert M, Kiely DG, Carlsen J, et al. Long-term safety profile of bosentan in patients with pulmonary arterial hypertension: results from the European Surveillance Program [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 300

    Google Scholar 

  2. Hoeper MM, Kiely DG, Carlsen J, et al. Safety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European Surveillance Program [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 300

    Google Scholar 

  3. Barst RJ, Langleben D, Badesch D, et al. The STRIDE-2 trial: does selectivity matter in endothelin antagonism for PAH? [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 300

    Google Scholar 

  4. Benza R, Mehta S, Koegh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension failing bosentan treatment [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 201

    Google Scholar 

  5. Korenblat P, Levy R, Slavin R, et al. Add-on omalizumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 358

    Google Scholar 

  6. Matz J, Melamed I, Ledford D, et al. Add-on omalizumab therapy significantly improves quality of life in patients with inadequatgely controlled sefere persistent asthma despite GINA 2002 step 4 treatment: INNOVATE [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 358 (plus poster)

    Google Scholar 

  7. Vogelmeier C, D’Urzo A, Jaspal M, et al. Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real-life study [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 628

    Google Scholar 

  8. D’Urzo A, Vogelmeier C, Jaspal M, et al. Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with a titration of Seretide (salmeterol/fluticasone) in patients with asthma: a real-life study [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 354

    Google Scholar 

  9. Tonnel AB, Bravo ML, Brun M. Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 540

    Google Scholar 

  10. Beeh K-M, Schelfout V, Gronke L, et al. QAB149: the first once-daily beta2-agonist with 24 hour bronchodilation [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 356 (plus poster)

    Google Scholar 

  11. Chuchalin AG, Tsoi AN, Richter K, et al. Cardiovascular safety of QAB149, a novel 24-hour beta2-agonist, in patients with stable asthma [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 356 (plus poster)

    Google Scholar 

  12. Naline E, Molimard M, Fairhurst R, et al. Duration and onset of action of QAB149, a novel 24-hour beta2-agonist, on the isolated human bronchus [abstract]. Proceedings of the American Thoracic Society 2005; 2 Suppl.: 356 (plus poster)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Ltd, Auckland, New Zealand

    Anoma Ranaweera

Authors
  1. Anoma Ranaweera
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranaweera, A. American Thoracic Society. Int J PHarm Med 19, 173–177 (2005). https://doi.org/10.2165/00124363-200519030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200519030-00005

Keywords

Search

Navigation